INSIGHT
For four decades, San Diego’s identity as a research town has been built on wet labs, sequencing machines, and the slow, expensive work of moving a molecule from a bench in Torrey Pines to a clinical trial. That story is still true. What has changed is the layer forming on top of it. Artificial intelligence is working its way into how the region’s scientists select drug targets, interpret genomes, and design proteins.
In addition, deciding which programs are worth funding, and the capital flowing into the region increasingly reflects that shift. The convergence is not a rebranding exercise. It is a reordering of where the region’s research economy places its bets.
A Cluster Built for Convergence
San Diego has long ranked as a top three market for life sciences in the United States, trailing only Boston and the Bay Area in concentration. The infrastructure behind that ranking is unusually dense for a region of its size. UC San Diego, Scripps Research, the Salk Institute, and Sanford Burnham Prebys sit within a short drive of one another, surrounded by the incubators, contract labs, and specialized service firms that let a discovery become a company without leaving the county. That geography matters more than it used to. AI applied to biology is a data problem before it is a computing problem, and the data lives inside sequencing operations, clinical networks, and research institutions that happen to be clustered in the same few square miles.
The region’s genomics heritage, anchored by companies that commercialized sequencing at scale, produced exactly the kind of large, structured biological datasets that machine learning models require. The result is a set of local companies that describe themselves in two vocabularies at once. Drug discovery platforms now talk about model architectures alongside binding affinities. Diagnostics firms describe algorithms as central to their products rather than as features layered on top.
Capital Is Choosing Sides
The funding picture tells the clearest version of this story. San Diego life sciences companies raised roughly $1.7 billion in venture capital through the first half of 2026, already approaching the full-year total for 2025, according to a second-quarter analysis of the regional market. Nearly half of second-quarter dollars went to companies with drugs in mid-stage trials, a sign that investors are favoring programs with clinical evidence behind them. More striking is the composition.
Regional brokerage analysis found that AI and life sciences together accounted for roughly 92% of San Diego venture funding year to date in 2026, a sharp concentration compared with 2021, when capital spread more evenly across software, information technology, and other sectors. Two verticals now absorb almost everything. Concentration of that kind cuts both ways. It gives the region a clear identity and a deep bench of specialized investors who understand long development timelines. It also means the local research economy rises and falls with the fortunes of a narrow band of science.
The Adoption Curve Is Still Early
Enthusiasm has outpaced implementation. A regional economic study of the cluster found that while several life sciences subindustries had deployed machine learning in meaningful ways, only about 18% of local firms were engaging with the technology at all, placing San Diego in the early stages of adoption. Subsequent years have narrowed that gap, but the pattern holds: a handful of well-capitalized platforms are moving quickly while a long tail of smaller firms watches.
Talent is the constraint most often cited. The scientists who can bridge computational methods and laboratory biology are scarce everywhere, and San Diego competes for them against technology employers offering compensation packages calibrated to a different industry.
What the Physical Market Says
Real estate offers an unsentimental read on the transition. The region’s life sciences sector employs roughly 62,000 workers across about 1,900 establishments and generates approximately $34 billion in direct economic output, yet lab vacancy sat near a cycle high through the middle of 2026 after several years of speculative construction delivered space faster than tenants could absorb it.
Some of that oversupply is a timing problem. Some of it reflects genuine change in what research organizations need. Computational work requires different facilities than traditional bench science, and companies building around AI-driven discovery are making different square-footage calculations than the biotechs that leased space during the last expansion.
Reading the Next Chapter
The near-term variables are known. Federal research funding, which underwrites a substantial share of the region’s institutional science, has grown less predictable. Venture investors have become more selective about stage and evidence. Consolidation continues across the life sciences industry, with several of the largest acquisitions in biotech history involving San Diego companies.
What is less clear is whether the convergence now underway produces a genuinely different kind of research economy or simply a faster version of the existing one. The region has assembled the ingredients: the data, the institutions, the investors, and the physical proximity that has always been its quiet advantage. The question San Diego is working through, company by company, is what those ingredients build next.
Start the conversation
Looking for a team who understands where you’re headed and how to help you get there? Whether you’re building something new, managing growth or preserving success, let’s talk.